Redirecting to https://www.newswire.ca/news-releases/health-canada-approves-additional-indication-for-nubeqa-r-darolutamide-for-the-treatment-of-metastatic-castration-sensitive-prostate-cancer-mcspc-in-combination-with-docetaxel-807171074.html